DaYan BioMedical International Co., Ltd. Q4 2025 Financial Report
NQ Score
67/100
N1 Content Completeness
7
Key facts
- DaYan BioMedical International Co., Ltd. Q4 2025 Financial Report
- DaYan BioMedical International Co., Ltd. reported Q4 2025 basic EPS of 0.51, operating revenue of 1.895 billion, and net income after tax of 338 million.
- Source: TWSE
- Date: Mon Dec 01 2025 09:00:00 GMT+0900 (Japan Standard Time)
Direct answer
DaYan BioMedical International Co., Ltd. reported Q4 2025 basic EPS of 0.51, operating revenue of 1.895 billion, and net income after tax of 338 million.
- Citation
- DaYan BioMedical International Co., Ltd. Q4 2025 Financial Report (Mon Dec 01 2025 09:00:00 GMT+0900 (Japan Standard Time)), TWSE
- Source
- TWSE
- Date
- Mon Dec 01 2025 09:00:00 GMT+0900 (Japan Standard Time)
AI Summary (NQ-processed)
DaYan BioMedical International Co., Ltd. reported Q4 2025 basic EPS of 0.51, operating revenue of 1.895 billion, and net income after tax of 338 million.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What are the key facts in this article?
- A: DaYan BioMedical International Co., Ltd. reported Q4 2025 basic EPS of 0.51, operating revenue of 1.895 billion, and net income after tax of 338 million.
- Q: What is the direct answer?
- A: DaYan BioMedical International Co., Ltd. reported Q4 2025 basic EPS of 0.51, operating revenue of 1.895 billion, and net income after tax of 338 million.
- Q: What is the source and date?
- A: Source: https://openapi.twse.com.tw/financial/twse-fin-7780-2025Q4 | Date: Mon Dec 01 2025 09:00:00 GMT+0900 (Japan Standard Time)